Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Titel:
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Auteur:
Lu, Shun Wang, Jie Cheng, Ying Mok, Tony Chang, Jianhua Zhang, Li Feng, Jifeng Tu, Hai-Yan Wu, Lin Zhang, Yiping Luft, Alexander Zhou, Jian-ying Ma, Zhiyong Lu, You Hu, Chengping Shi, Yuankai Ying, Kejing Zhong, Hua Poddubskaya, Elena Soo, Ross A Chia, Yee Hong Li, Ang Li, Amy Wu, Yi-Long